Nutriband Inc. (NTRB): Price and Financial Metrics
NTRB Price/Volume Stats
| Current price | $2.48 | 52-week high | $5.15 |
| Prev. close | $2.38 | 52-week low | $1.92 |
| Day low | $2.40 | Volume | 1,200 |
| Day high | $2.49 | Avg. volume | 27,204 |
| 50-day MA | $3.37 | Dividend yield | N/A |
| 200-day MA | $3.40 | Market Cap | 19.43M |
NTRB Stock Price Chart Interactive Chart >
NTRB Stock Summary
- With a market capitalization of $20,757,848, NUTRIBAND INC has a greater market value than only 9.61% of US stocks.
- NTRB's price/sales ratio is 9.11; that's higher than the P/S ratio of 88.88% of US stocks.
- With a year-over-year growth in debt of 937.8%, NUTRIBAND INC's debt growth rate surpasses 98.64% of about US stocks.
- If you're looking for stocks that are quantitatively similar to NUTRIBAND INC, a group of peers worth examining would be AUPH, TMDX, INVE, NXGN, and RELY.
- NTRB's SEC filings can be seen here. And to visit NUTRIBAND INC's official web site, go to nutriband.com.
NTRB Valuation Summary
- In comparison to the median Healthcare stock, NTRB's EV/EBIT ratio is 136.29% lower, now standing at -4.5.
- NTRB's price/earnings ratio has moved up 174.1 over the prior 71 months.
Below are key valuation metrics over time for NTRB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NTRB | 2023-09-18 | 9.1 | 3.0 | -4.5 | -4.5 |
| NTRB | 2023-09-15 | 9.3 | 3.1 | -4.6 | -4.6 |
| NTRB | 2023-09-14 | 9.0 | 3.0 | -4.5 | -4.4 |
| NTRB | 2023-09-13 | 8.9 | 2.9 | -4.4 | -4.4 |
| NTRB | 2023-09-12 | 8.8 | 2.9 | -4.4 | -4.4 |
| NTRB | 2023-09-11 | 9.8 | 3.2 | -4.8 | -4.8 |
NTRB Price Target
For more insight on analysts targets of NTRB, see our NTRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Nutriband Inc. (NTRB) Company Bio
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida
Latest NTRB News From Around the Web
Below are the latest news stories about NUTRIBAND INC that investors may wish to consider to help them evaluate NTRB as an investment opportunity.
Nutriband Unveils Groundbreaking Innovation in Transdermal MedicationsRevolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety |
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent TechnologyNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. |
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has been shortlisted for 5 awards at the Pharma Industry Awards 2023. |
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2023. |
Nutriband Inc. Announces Donovan McNabb as AI Tape Brand AmbassadorNutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announces that it has engaged former 6-time Pro-Bowl NFL quarterback, Donovan McNabb as a brand ambassador for its Active Intelligence Tape ("AI Tape") consumer sports recovery tape brand. |
NTRB Price Returns
| 1-mo | -27.38% |
| 3-mo | 21.87% |
| 6-mo | -29.14% |
| 1-year | -37.59% |
| 3-year | -66.93% |
| 5-year | -92.20% |
| YTD | -31.20% |
| 2022 | -64.24% |
| 2021 | -32.80% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...